## PROGRAMME

### THURSDAY 17 SEPTEMBER 2015

### EDUCATION DAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-09.00</td>
<td>Registration</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td><strong>E1: Opening words</strong></td>
</tr>
</tbody>
</table>
| 09.00-09.30 | INV020 Gene therapy – current status and future direction  
Hildegard Bünning, Hannover Medical School; German Center for Infection Research (DZIF), partner site Hannover-Braunschweig; University of Cologne |
| 09.30-11.00 | **E2a: Recent development of gene transfer vectors and therapeutic oligonucleotides – towards clinical trials**  
Chair: Andy Baker |
| 09.30-10.00 | INV021 Considerations and options for use as a vector for gene therapy  
Andy Baker |
| 10.00-10.30 | INV022 Update on the use of adenovirus for immunotherapy  
Vincenzo Cerullo |
| 10.30-11.00 | INV023 Oligonucleotide therapies  
C. I. Edvard Smith |
| 11.00-11.30 | **E2b: Large-scale vector production**  
Chair: Andy Baker |
| 11.00-11.30 | INV024 The challenges in large-scale viral vector production  
Hanna Lesch, FinVector Vision Therapies Ltd; FKD Therapies; A.I. Virtanen Institute, University of Eastern Finland, Kuopio |
| 11.30-12.30 | Lunch                                      |
| 12.30-13.30 | **E3a: General principles on vector testing in vivo: biodistribution, genotoxicity, general safety**  
Chair: Manfred Schmidt |
| 12.30-13.00 | INV026 A mouse is not a pig is not a human – choosing a relevant model to mimic human diseases  
Jenni Huusko, A.I. Virtanen Institute, University of Eastern Finland, Kuopio |
| 13.00-13.30 | INV025 Tracking vector safety in gene therapy  
Manfred Schmidt, DKFZ and National Center of Tumor Diseases (NCT) Heidelberg |
## PROGRAMME

### THURSDAY 17 SEPTEMBER 2015

### EDUCATION DAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13.30-14.00  | **E3b: Update of gene and cell therapy of chronic diseases**  
**Chair:** Manfred Schmidt |
| 13.30-14.00  | **INV027** Update of gene and cell therapy of chronic diseases, cardiovascular VEGF gene therapy and therapeutic angiogenesis  
*Marja Hedman, University of Eastern Finland; Kuopio University Hospital* |
| 14.00-14.30  | Afternoon break                                                                           |
| 14.30-15.30  | **E4a: Recent development of cancer therapy**  
**Chair:** Angelica Loskog |
| 14.30-15.00  | **INV028** Update on gene and cell therapy of glioblastoma  
*Hrvoje Miletic, University of Bergen; Haukeland University Hospital, Bergen* |
| 15.00-15.30  | **INV029** Immunostimulatory gene therapy  
*Angelica Loskog, Uppsala University* |
| 15.30-16.00  | **E4b: Update of gene and cell therapy of rare diseases**  
**Chair:** Angelica Loskog |
| 15.30-16.00  | **INV030** Gene therapy for rare diseases  
*Alessandra Biffi* |